Precigen announces positive interim phase 1 data for prgn-3006 ultracar-t® in relapsed or refractory acute myeloid leukemia

Germantown, md., dec. 13, 2021 /prnewswire/ -- precigen, inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented positive interim data at the 63rd ash annual meeting and exposition (abstract# 825) from the ongoing phase 1/1b clinical study of prgn-3006 ultracar-t® in patients with relapsed or refractory (r/r) acute myeloid leukemia (aml) and higher risk myelodysplastic syndromes (mds) (clinical trial identifier: nct03927261).
PGEN Ratings Summary
PGEN Quant Ranking